New hope for skin disease: major trial tests 4 treatments
NCT ID NCT07463040
First seen Mar 24, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This large Phase 3 trial in Ethiopia will test four different drug combinations against the standard treatment for cutaneous leishmaniasis, a skin disease caused by a parasite. About 900 people aged 4 to 65 with confirmed infection will be hospitalized and treated for up to 180 days. The goal is to see which treatment works best to heal all skin lesions by day 90.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS LEIHMANIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
ALERT Hospital
Addis Ababa, Ethiopia
Contact
Contact Email: •••••@•••••
-
Arba Minch General Hospital
Arba Minch, Ethiopia
Contact Email: •••••@•••••
Contact
-
Boru Meda General Hospital
Boru, Ethiopia
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.